Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 125
Single User License Price INR 9065
Corporate User License Price USD 375
Corporate User License Price INR 27195
Site License Price USD 250
Site License Price INR 18130
Request a Quote

Report Title

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review

Quote Request for License Type
License Type Price  
Single User License USD 125
Site License USD 250
Enterprise Wide License USD 375
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review


Quote Request for License Type
License Type Price  
Single User License USD 125
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review



Executive Summary

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK's vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Apr 26,2017: GSK delivers another quarter of continued progress

Mar 22,2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis

Feb 16,2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms

Feb 08,2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016

Jan 19,2017: Abbas Hussain to leave GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

GlaxoSmithKline Plc-Key Facts 6

GlaxoSmithKline Plc-Key Employees 7

GlaxoSmithKline Plc-Key Employee Biographies 8

GlaxoSmithKline Plc-Major Products and Services 9

GlaxoSmithKline Plc-Pharmaceutical Pipeline Products Data 10

GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Pipeline Products by Development Phase 12

GlaxoSmithKline Plc-History 13

GlaxoSmithKline Plc-Company Statement 34

GlaxoSmithKline Plc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Joint Venture 48

Section 2-Company Analysis 50

GlaxoSmithKline Plc-Business Description 50

GlaxoSmithKline Plc-Corporate Strategy 51

GlaxoSmithKline Plc-SWOT Analysis 52

SWOT Analysis-Overview 52

GlaxoSmithKline Plc-Strengths 52

GlaxoSmithKline Plc-Weaknesses 53

GlaxoSmithKline Plc-Opportunities 54

GlaxoSmithKline Plc-Threats 55

GlaxoSmithKline Plc-Key Competitors 56

Section 3-Company Financial Ratios 57

Financial Ratios-Capital Market Ratios 57

Financial Ratios-Annual Ratios 58

Performance Chart 61

Financial Performance 61

Financial Ratios-Interim Ratios 62

Financial Ratios-Ratio Charts 63

Section 4-Company's Lifesciences, Power Financial Deals and Alliances 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65

GlaxoSmithKline Plc, Recent Deals Summary 66

Section 5-Company's Recent Developments 67

Apr 26, 2017: GSK delivers another quarter of continued progress 67

Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 70

Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 72

Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 73

Jan 19, 2017: Abbas Hussain to leave GSK 89

Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 90

Dec 19, 2016: GSK announces Board changes 91

Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 92

Oct 06, 2016: CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration 98

Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 99

Section 6-Appendix 100

Methodology 100

Ratio Definitions 100

About GlobalData 104

Contact Us 104

Disclaimer 104

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Pipeline Products by Development Phase 12

GlaxoSmithKline Plc, Performance Chart (2012-2016) 61

GlaxoSmithKline Plc, Ratio Charts 63

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 65

List of Tables

GlaxoSmithKline Plc, Key Facts 6

GlaxoSmithKline Plc, Key Employees 7

GlaxoSmithKline Plc, Key Employee Biographies 8

GlaxoSmithKline Plc, Major Products and Services 9

GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area (Cont...1) 11

GlaxoSmithKline Plc, Number of Pipeline Products by Development Stage 12

GlaxoSmithKline Plc, History 13

GlaxoSmithKline Plc, Other Locations 36

GlaxoSmithKline Plc, Subsidiaries 36

GlaxoSmithKline Plc, Joint Venture 48

GlaxoSmithKline Plc, Key Competitors 56

GlaxoSmithKline Plc, Ratios based on current share price 57

GlaxoSmithKline Plc, Annual Ratios 58

GlaxoSmithKline Plc, Annual Ratios (Cont...1) 59

GlaxoSmithKline Plc, Annual Ratios (Cont...2) 60

GlaxoSmithKline Plc, Interim Ratios 62

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65

GlaxoSmithKline Plc, Recent Deals Summary 66

Currency Codes 100

Capital Market Ratios 100

Equity Ratios 101

Profitability Ratios 101

Cost Ratios 102

Liquidity Ratios 102

Leverage Ratios 103

Efficiency Ratios 103

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Sophiris Bio Inc, Sanofi, Pfizer Inc, Oragenics Inc, Novartis AG, NewLink Genetics Corp, Napp Pharmaceuticals Ltd, Merck & Co Inc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Cascadian Therapeutics Inc, Cardiome Pharma Corp, Bristol-Myers Squibb Company, Biofarm SA, AstraZeneca Plc, Aquinox Pharmaceuticals Inc, Amgen Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand